Despite extensive research interest in FGF-23, debate remains over whether the observed relationship with MACE is likely to be causal or a result of unmeasured confounding factors, possibly reflecting differences in kidney function, secondary hyperparathyroidism, or treatment for renal bone disease.20 The gene discussed is FGF23; the disease is secondary hyperparathyroidism.